These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 11266932)
1. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Jacobsen W; Serkova N; Hausen B; Morris RE; Benet LZ; Christians U Transplant Proc; 2001; 33(1-2):514-5. PubMed ID: 11266932 [No Abstract] [Full Text] [Related]
2. Structural elucidation by electrospray mass spectrometry: an approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD. Vidal C; Kirchner GI; Sewing KF J Am Soc Mass Spectrom; 1998 Dec; 9(12):1267-74. PubMed ID: 9835072 [TBL] [Abstract][Full Text] [Related]
3. Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus. Strom T; Haschke M; Boyd J; Roberts M; Arabshahi L; Marbach P; Christians U Ther Drug Monit; 2007 Dec; 29(6):743-9. PubMed ID: 18043471 [TBL] [Abstract][Full Text] [Related]
5. In vitro biotransformation of SDZ RAD: a new immunosuppressive macrolide in human liver microsomal preparations. Dannecker R; Vickers AE; Ubeaud G; Hauck C Transplant Proc; 1998 Aug; 30(5):2206. PubMed ID: 9723442 [TBL] [Abstract][Full Text] [Related]
6. Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry. Hallensleben K; Raida M; Habermehl G J Am Soc Mass Spectrom; 2000 Jun; 11(6):516-25. PubMed ID: 10833025 [TBL] [Abstract][Full Text] [Related]
7. Isolation from pig liver microsomes, identification by tandem mass spectrometry and in vitro immunosuppressive activity of an SDZ-RAD 17,18,19,20,21,22-tris-epoxide. Lhoëst GJ; Gougnard TY; Verbeeck RK; Maton N; Dehoux JP; Wallemacq P; Schüler W; Latinne D J Mass Spectrom; 2000 Mar; 35(3):454-60. PubMed ID: 10767777 [TBL] [Abstract][Full Text] [Related]
8. Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. Boernsen KO; Egge-Jacobsen W; Inverardi B; Strom T; Streit F; Schiebel HM; Benet LZ; Christians U J Mass Spectrom; 2007 Jun; 42(6):793-802. PubMed ID: 17511017 [TBL] [Abstract][Full Text] [Related]
9. The macrolide everolimus forms an unusual metabolite in animals and humans: identification of a phosphocholine ester. Zollinger M; Sayer C; Dannecker R; Schuler W; Sedrani R Drug Metab Dispos; 2008 Aug; 36(8):1457-60. PubMed ID: 18448571 [TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of pre-rapamycin, the first macrocyclic intermediate in the biosynthesis of the immunosuppressant rapamycin by S. hygroscopicus. Gregory MA; Gaisser S; Lill RE; Hong H; Sheridan RM; Wilkinson B; Petkovic H; Weston AJ; Carletti I; Lee HL; Staunton J; Leadlay PF Angew Chem Int Ed Engl; 2004 May; 43(19):2551-3. PubMed ID: 15127450 [No Abstract] [Full Text] [Related]
11. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes. Streit F; Christians U; Schiebel HM; Meyer A; Sewing KF Drug Metab Dispos; 1996 Nov; 24(11):1272-8. PubMed ID: 8937863 [TBL] [Abstract][Full Text] [Related]
12. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. Kuhn B; Jacobsen W; Christians U; Benet LZ; Kollman PA J Med Chem; 2001 Jun; 44(12):2027-34. PubMed ID: 11384247 [TBL] [Abstract][Full Text] [Related]
13. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Christians U; Sattler M; Schiebel HM; Kruse C; Radeke HH; Linck A; Sewing KF Drug Metab Dispos; 1992; 20(2):186-91. PubMed ID: 1352208 [TBL] [Abstract][Full Text] [Related]
14. Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Picard N; Djebli N; Sauvage FL; Marquet P Drug Metab Dispos; 2007 Mar; 35(3):350-5. PubMed ID: 17151193 [TBL] [Abstract][Full Text] [Related]
16. In vitro immunosuppressive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry. Lhoëst G; Hertsens R; Verbeeck RK; Maton N; Wallemacq P; Dehoux JP; Latinne D J Mass Spectrom; 2001 Aug; 36(8):889-901. PubMed ID: 11523088 [TBL] [Abstract][Full Text] [Related]
17. Cleavage of the cyclohexyl-subunit of rapamycin results in loss of immunosuppressive activity. Sedrani R; Jones LH; Jutzi-Eme AM; Schuler W; Cottens S Bioorg Med Chem Lett; 1999 Feb; 9(3):459-62. PubMed ID: 10091702 [TBL] [Abstract][Full Text] [Related]
18. Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients. Strom T; Haschke M; Zhang YL; Bendrick-Peart J; Boyd J; Roberts M; Arabshahi L; Marbach P; Christians U Ther Drug Monit; 2007 Oct; 29(5):592-9. PubMed ID: 17898649 [TBL] [Abstract][Full Text] [Related]
19. Everolimus and sirolimus in transplantation-related but different. Klawitter J; Nashan B; Christians U Expert Opin Drug Saf; 2015 Jul; 14(7):1055-70. PubMed ID: 25912929 [TBL] [Abstract][Full Text] [Related]
20. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Schuurman HJ; Ringers J; Schuler W; Slingerland W; Jonker M Transplantation; 2000 Mar; 69(5):737-42. PubMed ID: 10755519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]